Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-29

FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)

View source ↗

Summary

The FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate), indicating an approved modification to its labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VUMERITY (diroximel fumarate)

Snippet

SUPPL AP for VUMERITY (DIROXIMEL FUMARATE)